Beijing Centergate Technologies (000931.SZ) Announces Acceptance of Consistency Evaluation Application for Buspirone Hydrochloride Tablets

Stock News12-19 16:06

Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) disclosed that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the "Acceptance Notice" from the National Medical Products Administration for the consistency evaluation application of Buspirone Hydrochloride Tablets (specifications: 5mg, 10mg). Buspirone, the first non-benzodiazepine anxiolytic drug, acts as a 5-HT1A (serotonin) receptor agonist. By selectively binding to 5-HT1A receptors in the brain, it reduces excessive 5-HT activity in anxiety disorders, producing an anti-anxiety effect. Its primary clinical advantage is the absence of drug dependence and withdrawal reactions, ensuring high safety. Buspirone Hydrochloride Tablets are indicated for various anxiety disorders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162567889?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162567889","market":"nz","top_or_hot":-1,"title":"Beijing Centergate Technologies (000931.SZ) Announces Acceptance of Consistency Evaluation Application for Buspirone Hydrochloride Tablets","media":"Stock News","content":"<p>Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) disclosed that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the National Medical Products Administration for the consistency evaluation application of Buspirone Hydrochloride Tablets (specifications: 5mg, 10mg). Buspirone, the first non-benzodiazepine anxiolytic drug, acts as a 5-HT1A (serotonin) receptor agonist. By selectively binding to 5-HT1A receptors in the brain, it reduces excessive 5-HT activity in anxiety disorders, producing an anti-anxiety effect. Its primary clinical advantage is the absence of drug dependence and withdrawal reactions, ensuring high safety. Buspirone Hydrochloride Tablets are indicated for various anxiety disorders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Centergate Technologies (000931.SZ) Announces Acceptance of Consistency Evaluation Application for Buspirone Hydrochloride Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Centergate Technologies (000931.SZ) Announces Acceptance of Consistency Evaluation Application for Buspirone Hydrochloride Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-19 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) disclosed that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the National Medical Products Administration for the consistency evaluation application of Buspirone Hydrochloride Tablets (specifications: 5mg, 10mg). Buspirone, the first non-benzodiazepine anxiolytic drug, acts as a 5-HT1A (serotonin) receptor agonist. By selectively binding to 5-HT1A receptors in the brain, it reduces excessive 5-HT activity in anxiety disorders, producing an anti-anxiety effect. Its primary clinical advantage is the absence of drug dependence and withdrawal reactions, ensuring high safety. Buspirone Hydrochloride Tablets are indicated for various anxiety disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1162567889","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162567889","pubTimestamp":1766131577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) disclosed that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK0178":"特色小镇","000931":"中关村","BK0075":"新三板","BK0239":"医药制造"},"translate_title":"北京中门科技（000931.SZ）公布盐酸丁螺环酮片一致性评价申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000931":1},"content_text":"Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) disclosed that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" from the National Medical Products Administration for the consistency evaluation application of Buspirone Hydrochloride Tablets (specifications: 5mg, 10mg). Buspirone, the first non-benzodiazepine anxiolytic drug, acts as a 5-HT1A (serotonin) receptor agonist. By selectively binding to 5-HT1A receptors in the brain, it reduces excessive 5-HT activity in anxiety disorders, producing an anti-anxiety effect. Its primary clinical advantage is the absence of drug dependence and withdrawal reactions, ensuring high safety. Buspirone Hydrochloride Tablets are indicated for various anxiety disorders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162567889","isCrawlerRequest":true}